PAVmed (NASDAQ:PAVM) Share Price Crosses Below Fifty Day Moving Average – Should You Sell?

Shares of PAVmed Inc. (NASDAQ:PAVM) crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $5.50 and traded as low as $4.89. PAVmed shares last traded at $5.20, with a volume of 9,380 shares traded.

Wall Street Analyst Weigh In

Several research firms have issued reports on PAVM. Ascendiant Capital Markets reduced their price objective on PAVmed from $65.00 to $56.00 and set a “buy” rating on the stock in a report on Monday, June 8th. Weiss Ratings reissued a “sell (d)” rating on shares of PAVmed in a research note on Friday, July 17th. Finally, Wall Street Zen upgraded PAVmed from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $56.00.

PAVmed Stock Up 9.7%

The firm’s 50 day moving average price is $5.50 and its 200-day moving average price is $7.89. The company has a current ratio of 2.02, a quick ratio of 2.02 and a debt-to-equity ratio of 0.70. The company has a market cap of $5.20 million, a P/E ratio of -0.14 and a beta of 0.54.

PAVmed (NASDAQ:PAVM) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.48). PAVmed had a negative return on equity of 146.19% and a negative net margin of 21,914.12%.The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.07 million. As a group, equities research analysts expect that PAVmed Inc. will post -2.74 EPS for the current year.

Institutional Trading of PAVmed

A hedge fund recently raised its position in PAVmed stock. Jane Street Group LLC grew its stake in PAVmed Inc. (NASDAQ:PAVM) by 392.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 52,676 shares of the company’s stock after purchasing an additional 41,990 shares during the quarter. Jane Street Group LLC owned about 0.31% of PAVmed worth $32,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 19.93% of the company’s stock.

PAVmed Company Profile

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.